Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
作者信息
Idle J R, Smith R L
出版信息
Drug Metab Rev. 1979;9(2):301-17. doi: 10.3109/03602537908993896.
PMID:158499
Abstract
摘要
相似文献
1
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
Drug Metab Rev. 1979;9(2):301-17. doi: 10.3109/03602537908993896.
2
Genetically determined defcts of oxidation at carbon centres of drugs.
Lancet. 1978 Apr 29;1(8070):943-4. doi: 10.1016/s0140-6736(78)90724-9.
3
[Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
Internist (Berl). 1983 Mar;24(3):117-27.
4
Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation.
J Pharm Pharmacol. 1979 May;31(5):350-2. doi: 10.1111/j.2042-7158.1979.tb13520.x.
5
[Heritable polymorphisms in oxidative drug metabolism].
Duodecim. 1990;106(5):408-14.
6
Polymorphism of carbon oxidation of drugs and clinical implications.
Br Med J. 1978 Sep 2;2(6138):655-7. doi: 10.1136/bmj.2.6138.655.
7
[Genetic polymorphism of the hepatic metabolism of drugs].
Gastroenterol Clin Biol. 1985 Jun-Jul;9(6-7):522-31.
8
Pharmacogenetic polymorphism of drug metabolism.
N Z Med J. 1984 Aug 22;97(762):567-9.
9
Polymorphic drug oxidation in humans.
Fed Proc. 1984 May 15;43(8):2298-302.
10
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
引用本文的文献
1
Approaches to deorphanization of human and microbial cytochrome P450 enzymes.
Biochim Biophys Acta. 2011 Jan;1814(1):139-45. doi: 10.1016/j.bbapap.2010.05.005. Epub 2010 May 20.
2
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin.
Eur J Clin Pharmacol. 2009 Aug;65(8):789-93. doi: 10.1007/s00228-009-0651-6. Epub 2009 Apr 23.
3
Drug metabolism and pharmacogenetics: the British contribution to fields of international significance.
Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S89-99. doi: 10.1038/sj.bjp.0706466.
4
Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing.
Eur J Clin Pharmacol. 2003 Oct;59(7):521-6. doi: 10.1007/s00228-003-0654-7. Epub 2003 Sep 6.
5
Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?
Am J Hum Genet. 1997 Feb;60(2):265-71.
6
Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.
J Psychiatry Neurosci. 1994 Jan;19(1):30-44.
7
An assessment of short-cut procedures for studying drug metabolism in vivo using amobarbital as a model drug.
Eur J Clin Pharmacol. 1982;22(3):229-33. doi: 10.1007/BF00545220.
8
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
9
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Br J Clin Pharmacol. 1983 Mar;15(3):317-21. doi: 10.1111/j.1365-2125.1983.tb01505.x.
10
Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolism.
Br Med J (Clin Res Ed). 1981 Aug 22;283(6290):537-42. doi: 10.1136/bmj.283.6290.537.
Zotero 插件